DiaMedica Therapeutics Inc
NASDAQ:DMAC
During the last 3 months DiaMedica Therapeutics Inc insiders have not bought any shares, and have not sold any shares. The stock price has dropped by 16% over this period (open performance analysis).
The last transaction was made on
Nov 25, 2025
by
Trill Ab
, who
bought
626.8k USD
worth of 
DMAC shares.
During the last 3 months DiaMedica Therapeutics Inc insiders have not bought any shares, and have not sold any shares. The stock price has dropped by 16% over this period (open performance analysis).
The last transaction was made on
Nov 25, 2025
by
Trill Ab
, who
bought
626.8k USD
worth of DMAC shares.
DiaMedica Therapeutics Inc
Glance View
DiaMedica Therapeutics, Inc. operates as a clinical stage biopharmaceutical company, which engages in the development of novel recombinant proteins. The company is headquartered in Minneapolis, Minnesota and currently employs 14 full-time employees. The company went IPO on 2008-01-04. The firm is focused on developing treatments for neurological and kidney diseases, such as acute ischemic stroke (AIS) and chronic kidney disease (CKD). The firm's lead product DM199 mimics the behavior of naturally occurring human kallikrein-1 (KLK1) proteins to preserve and restore circulation to stroke-damaged tissue and improve overall kidney function. KLK1 is a serine protease, or protein, produced primarily in the kidneys, pancreas and salivary glands. DM199 therapy has the potential to improve circulation and overall function of critical systems, as well as reduce inflammation and oxidative stress. The firm also has other product pipelines for IgA Nephropathy and African Americans with CKD.
What is Insider Trading?
Insider trading refers to the buying or selling of a company’s stock by individuals with access to non-public, material information about the company.
While legal insider trading occurs when insiders follow disclosure rules, illegal insider trading involves trading based on confidential information and is prohibited by law.
Why is Insider Trading Important?
It isn't a coincidence that corporate executives seem to always buy at the right times. After all, they have access to every bit of company information you could ever want.
However, the fact that company executives have unique insights doesn't mean that individual investors are always left in the dark. Insider trading data is out there for all who want to use it.
Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
